Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia
Conditions
Interventions
Olezarsen
Placebo
Locations
168
United States
Alabama Clinical Therapeutics, LLC Alabaster
Birmingham, Alabama, United States
Heart Center Research PC
Huntsville, Alabama, United States
Cardiovascular Research Foundation of Southern California
Beverly Hills, California, United States
Westside Medical Associates of Los Angeles
Beverly Hills, California, United States
Diabetes/Lipid Management & Research Center
Huntington Beach, California, United States
University of California, San Diego (UCSD)
La Jolla, California, United States
Start Date
November 21, 2022
Primary Completion Date
August 8, 2024
Completion Date
June 9, 2025
Last Updated
February 10, 2026
NCT07547098
NCT01399385
NCT00353782
NCT07491315
NCT07256249
NCT07487363
Lead Sponsor
Ionis Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions